CATX vs. AXGN, CBLL, AVNS, IRMD, SIBN, TMCI, KIDS, DCTH, CLPT, and SMLR
Should you be buying Perspective Therapeutics stock or one of its competitors? The main competitors of Perspective Therapeutics include AxoGen (AXGN), CeriBell (CBLL), Avanos Medical (AVNS), Iradimed (IRMD), SI-BONE (SIBN), Treace Medical Concepts (TMCI), OrthoPediatrics (KIDS), Delcath Systems (DCTH), ClearPoint Neuro (CLPT), and Semler Scientific (SMLR). These companies are all part of the "medical equipment" industry.
Perspective Therapeutics vs.
AxoGen (NASDAQ:AXGN) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends.
AxoGen received 432 more outperform votes than Perspective Therapeutics when rated by MarketBeat users. However, 95.65% of users gave Perspective Therapeutics an outperform vote while only 72.76% of users gave AxoGen an outperform vote.
AxoGen has a net margin of -7.91% compared to Perspective Therapeutics' net margin of -4,096.66%. AxoGen's return on equity of -14.91% beat Perspective Therapeutics' return on equity.
AxoGen currently has a consensus target price of $18.33, indicating a potential upside of 1.85%. Perspective Therapeutics has a consensus target price of $15.14, indicating a potential upside of 443.73%. Given Perspective Therapeutics' higher possible upside, analysts clearly believe Perspective Therapeutics is more favorable than AxoGen.
In the previous week, Perspective Therapeutics had 1 more articles in the media than AxoGen. MarketBeat recorded 3 mentions for Perspective Therapeutics and 2 mentions for AxoGen. AxoGen's average media sentiment score of 0.44 beat Perspective Therapeutics' score of 0.00 indicating that AxoGen is being referred to more favorably in the media.
80.3% of AxoGen shares are held by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are held by institutional investors. 7.0% of AxoGen shares are held by insiders. Comparatively, 3.5% of Perspective Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
AxoGen has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Perspective Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.
AxoGen has higher revenue and earnings than Perspective Therapeutics.
Summary
AxoGen beats Perspective Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Perspective Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Perspective Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:CATX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free CATX Stock Alerts